Diagnostic accuracy of cerebrospinal fluid and serum-isolated extracellular vesicles for glioblastoma: a systematic review and meta-analysis. (1st November 2020)

• Record Type: Journal Article
• Authors: Jafari, Davod; Tiyuri, Amir; Rezaei, Elmnaz; Moradi, Yousef; Jafari, Rasool; Jokar Shoorijeh, Farzaneh; Barati, Mahmood
• Is Part Of: Expert review of molecular diagnostics. Volume 20:Number 11(2020)
• Page Start: 1075
• Page End: 1085
• Publication Date: 2020-11-01
• Subjects: Biomarkers -- exosomes -- extracellular vesicles -- glioblastoma -- meta-analysis; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2020.1844006
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Background: Glioblastoma (GBM) is the most malignant brain cancer because there are no available biopsy-free methods for the diagnosis or the preoperative early detection. In this regard, the development of a non- or minimally invasive methods for early detection could increase the survival rate of GBM patients. Methods: The present study aimed to assess the diagnostic accuracy of extracellular vesicles (EVs) derived RNAs, isolated from patients' CSF or serum for GBM diagnosis. For this purpose, we searched all literature databases and performed a backward and forward reference checking procedure to retrieve appropriate studies. We conducted a meta-analysis on EVs derived biomarkers as well as sensitivity analysis and meta-regression. Results: We identified EVs-derived 24 RNAs, which can diagnose GBM. The analyzed pooled data showed 76% sensitivity, 80% specificity, and 0.85 AUC, for 16 biomarkers. Besides, the pooled PLR, NLR, and DOR were 3.7, 0.30, and 12, respectively. Subgroup analysis did not show a significant difference between serum and CSF. Conclusions: According to the pooled sensitivity, specificity, and AUC for EVs derived biomarkers, we suggest that EVs-derived biomarkers might serve as a high potential and noninvasive diagnostic tool for GBM detection using serum and CSF samples.